학술논문
Where Are We and Where to Next?-The Future of Perianal Crohn's Disease Management.
Document Type
Academic Journal
Author
Anandabaskaran S; Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Hammersmith Campus, Imperial College London, London W12 0NN, UK.; Robin Phillip's Fistula Research Unit, St Mark's Hospital and Academic Institute, London HA1 3UJ, UK.; Faculty of Medicine, St Vincent's Clinical School, University of New South Wales, 390 Victoria Street, Darlinghurst, NSW 2010, Australia.; Hanna L; Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Hammersmith Campus, Imperial College London, London W12 0NN, UK.; Robin Phillip's Fistula Research Unit, St Mark's Hospital and Academic Institute, London HA1 3UJ, UK.; Iqbal N; Robin Phillip's Fistula Research Unit, St Mark's Hospital and Academic Institute, London HA1 3UJ, UK.; Department of Surgery and Cancer, South Kensington Campus, Imperial College London, London SW7 2BX, UK.; Constable L; Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Hammersmith Campus, Imperial College London, London W12 0NN, UK.; Tozer P; Robin Phillip's Fistula Research Unit, St Mark's Hospital and Academic Institute, London HA1 3UJ, UK.; Department of Surgery and Cancer, South Kensington Campus, Imperial College London, London SW7 2BX, UK.; Hart A; Robin Phillip's Fistula Research Unit, St Mark's Hospital and Academic Institute, London HA1 3UJ, UK.; Department of Surgery and Cancer, South Kensington Campus, Imperial College London, London SW7 2BX, UK.
Source
Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101606588 Publication Model: Electronic Cited Medium: Print ISSN: 2077-0383 (Print) Linking ISSN: 20770383 NLM ISO Abbreviation: J Clin Med Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2077-0383
Abstract
Perianal fistulizing Crohn's Disease (pCD) affects about 25% of patients with Crohn's Disease (CD). It remains a difficult entity to manage with a therapeutic ceiling of treatment success despite improving medical and surgical management. The refractory nature of the disease calls for an imminent need to better understand its immunopathogenesis and classification to better streamline our treatment options. In this article, we overview the current state of pCD management and discuss where the future of its management may lie.